{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T19:23:39Z","timestamp":1780428219112,"version":"3.54.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.14310\/horm.2002.1727","type":"journal-article","created":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T14:48:54Z","timestamp":1500907734000},"page":"115-123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications"],"prefix":"10.1007","volume":"16","author":[{"given":"Vasileios","family":"Tzortzis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Samarinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Zachos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Oeconomou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis L.","family":"Pisters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Bargiota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,30]]},"reference":[{"key":"16020115_CR1","doi-asserted-by":"publisher","first-page":"8225","DOI":"10.1200\/JCO.2005.03.5311","volume":"23","author":"CJ Ryan","year":"2005","unstructured":"Ryan CJ, Small EJ, 2005 Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate. J Clin Oncol 23: 8225\u20138231.","journal-title":"J Clin Oncol"},{"key":"16020115_CR2","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/cncr.20955","volume":"103","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo Yf, Freeman JL, Orihuela E, Goodwin JS, 2005 Increasing use of gonadotropin releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103: 1615.","journal-title":"Cancer"},{"key":"16020115_CR3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.eururo.2013.09.046","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J, et al, 2014 EAU guidelines on prostate cancer, part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65: 124\u2013137.","journal-title":"Eur Urol"},{"key":"16020115_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","volume":"360","author":"M Bolla","year":"2002","unstructured":"Bolla M, Collette L, Blank L, et al, 2002 Long term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 360: 103\u2013106.","journal-title":"Lancet"},{"key":"16020115_CR5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","volume":"7","author":"EM Messing","year":"2006","unstructured":"Messing EM, Manola J, Yao J, et al, 2006 Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7: 472\u2013479.","journal-title":"Lancet Oncol"},{"key":"16020115_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/archsurg.1941.01210140043004","volume":"43","author":"C Huggins","year":"1941","unstructured":"Huggins C, Hodges CV, 1941 Studies on prostate cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43: 209\u2013233.","journal-title":"Arch Surg"},{"key":"16020115_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J, et al, 2014 EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65: 467\u2013479.","journal-title":"Eur Urol"},{"key":"16020115_CR8","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1056\/NEJM199810083391504","volume":"339","author":"MA Eisenberger","year":"1998","unstructured":"Eisenberger MA, Blumenstein BA, Crawford ED, et al, 1998 Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339: 1036\u20131042.","journal-title":"N Engl J Med"},{"key":"16020115_CR9","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00345-016-1818-2","volume":"34","author":"DJ Rosario","year":"2016","unstructured":"Rosario DJ, Davey P, Green J, 2016 The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK. World J Urol 34: 1601\u20131609.","journal-title":"World J Urol"},{"key":"16020115_CR10","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMe0901737","volume":"360","author":"P Albertsen","year":"2009","unstructured":"Albertsen P, 2009 Androgen deprivation in prostate cancer-step by step. N Engl J Med 360: 2572\u20132574.","journal-title":"N Engl J Med"},{"key":"16020115_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jama.294.2.238","volume":"294","author":"N Sharifi","year":"2005","unstructured":"Sharifi N, Gulley J, Dahut W, 2005 Androgen deprivation therapy for prostate cancer. JAMA 294: 238\u2013244.","journal-title":"JAMA"},{"key":"16020115_CR12","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1206168","volume":"369","author":"JS Finkelstein","year":"2013","unstructured":"Finkelstein JS, Lee H, Burnett-Bowie SA, et al, 2013 Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 369: 1011\u20131022.","journal-title":"N Engl J Med"},{"key":"16020115_CR13","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/MED.0b013e3283398ee2","volume":"17","author":"CA Allan","year":"2010","unstructured":"Allan CA, McLachlan RI, 2010 Androgens and obesity. Curr Opin Endocrinol Diabetes Obes 17: 224\u2013232.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"16020115_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/ije\/dyq158","volume":"40","author":"JS Brand","year":"2011","unstructured":"Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT, 2011 Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol 40: 189\u2013207.","journal-title":"Int J Epidemiol"},{"key":"16020115_CR15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.urology.2007.08.035","volume":"71","author":"MR Smith","year":"2008","unstructured":"Smith MR, Lee H, Fallon M, Nathan DM, 2008 Adipocytokines, obesity and insulin resistance during combined androgen blockade for prostate cancer. Urology 71: 318\u2013322.","journal-title":"Urology"},{"key":"16020115_CR16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","volume":"87","author":"MR Smith","year":"2002","unstructured":"Smith MR, Finkelstein JS, McGovern FJ, et al, 2002 Change in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87: 599\u2013603.","journal-title":"J Clin Endocrinol Metab"},{"key":"16020115_CR17","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0959-8049(00)00084-8","volume":"36","author":"P Stone","year":"2000","unstructured":"Stone P, Hardy J, Huddart R, et al, 2000 Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 36: 1134\u20131141.","journal-title":"Eur J Cancer"},{"key":"16020115_CR18","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.numecd.2007.10.002","volume":"18","author":"M Zamboni","year":"2000","unstructured":"Zamboni M, Mazzali G, Fantin F, Rossi A, Di Francesco V, 2000 Sarcopenic obesity: a new category of obesity in the elderly. Nutr Metab Cardiovasc Dis 18: 388\u2013395.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"16020115_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/ggi.12579","volume":"16","author":"S Tian","year":"2016","unstructured":"Simiao Tian and Yang Xu, 2016 Association of sarcopenic obesity with the risk of all-cause mortality: A meta-analysis of prospective cohort studies. Geriatr Gerontol Int 16: 155\u2013166.","journal-title":"Geriatr Gerontol Int"},{"key":"16020115_CR20","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1590\/S1807-59322009000800012","volume":"64","author":"C Reis","year":"2009","unstructured":"Reis C, Liberman S, Pompeo AC, Srougi M, Halpern A, Filho WJ, 2009 Body composition alterations, energy expenditure and fat oxidation in elderly males suffering from prostate cancer, pre- and post-orchiectomy. Clinics (Sao Paulo) 64: 781\u2013784.","journal-title":"Clinics (Sao Paulo)"},{"key":"16020115_CR21","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.steroids.2013.05.001","volume":"78","author":"G Chazenbalk","year":"2013","unstructured":"Chazenbalk G, Singh P, Irge D, Shah A, Abbott D, Dumesic D, 2013 Androgens inhibit adipogenesis during human adipose stem cell commitment to preadipocyte formation. Steroids 78: 920\u2013926.","journal-title":"Steroids"},{"key":"16020115_CR22","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1210\/jcem.86.9.7851","volume":"86","author":"JC Smith","year":"2001","unstructured":"Smith JC, Bennett S, Evans LM, et al, 2001 The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86: 4261\u20134267.","journal-title":"J Clin Endocrinol Metab"},{"key":"16020115_CR23","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.eururo.2015.10.047","volume":"69","author":"L Bourke","year":"2016","unstructured":"Bourke L, Smith D, Steed L, et al, 2016 Exercise for men with prostate cancer: A systematic review and meta-analysis. Eur Urol 69: 693\u2013703.","journal-title":"Eur Urol"},{"key":"16020115_CR24","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00520-009-0694-3","volume":"18","author":"SN Culos-Reed","year":"2010","unstructured":"Culos-Reed SN, Robinson JW, Lau H, 2010 Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention. Support Care Cancer 18: 591\u2013599.","journal-title":"Support Care Cancer"},{"key":"16020115_CR25","doi-asserted-by":"crossref","unstructured":"Wall BA, Galv\u00e3o DA, Fatehee N, 2017 Exercise Improves VO2max and Body Composition in ADT-treated Prostate Cancer Patients. Med Sci Sports Exerc [Epub ahead of print].","DOI":"10.1249\/01.mss.0000517784.17673.03"},{"key":"16020115_CR26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11154-015-9323-2","volume":"16","author":"AM Traish","year":"2015","unstructured":"Traish AM, Zitzmann M, 2015 The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease. Rev Endocr Metab Disord 16: 249\u2013268.","journal-title":"Rev Endocr Metab Disord"},{"key":"16020115_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1055\/s-0030-1270521","volume":"43","author":"MI Ullah","year":"2011","unstructured":"Ullah MI, Washington T, Kazi M, Tamanna S, Koch CA, 2011 Testosterone deficiency as a risk factor for cardiovascular disease. Horm Metab Res 43: 153\u2013164.","journal-title":"Horm Metab Res"},{"key":"16020115_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1042\/cs1040195","volume":"104","author":"F Dockery","year":"2003","unstructured":"Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C, 2003 Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinemia. Clin Sci (London) 104: 195\u2013201.","journal-title":"Clin Sci (London)"},{"key":"16020115_CR29","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"NL Keating","year":"2006","unstructured":"Keating NL, O Malley AJ, Smith MR, 2006 Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24: 4448\u20134456.","journal-title":"J Clin Oncol"},{"key":"16020115_CR30","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.2337\/diab.43.11.1271","volume":"43","author":"GS Hotamisligil","year":"1994","unstructured":"Hotamisligil GS, Spiegelman BM, 1994 Tumor necrosis factor \u03b1: a key component of the obesity-diabetes link. Diabetes 43: 1271\u20131278.","journal-title":"Diabetes"},{"key":"16020115_CR31","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1191\/0961203304lu1094oa","volume":"13","author":"M Cutolo","year":"2004","unstructured":"Cutolo M, Sulli A, Capellino S, et al, 2004 Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus 13: 635\u2013638.","journal-title":"Lupus"},{"key":"16020115_CR32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11934-008-0035-y","volume":"9","author":"RM Smith","year":"2008","unstructured":"Smith RM, 2008 Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors. Curr Urol Rep 9: 197\u2013202.","journal-title":"Curr Urol Rep"},{"key":"16020115_CR33","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","volume":"27","author":"SM Alibhai","year":"2009","unstructured":"Alibhai SM, Duong-Hua M, Sutradhar R, et al, 2009 Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 27: 3452\u20133458.","journal-title":"J Clin Oncol"},{"key":"16020115_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jnci\/djp404","volume":"102","author":"NL Keating","year":"2010","unstructured":"Keating NL, O\u2019Malley J, Stephen J, Smith MR, 2010 Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102: 39\u201346.","journal-title":"J Natl Cancer Inst"},{"key":"16020115_CR35","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.juro.2014.12.027","volume":"193","author":"HT Tsai","year":"2015","unstructured":"Tsai HT, Keating NL, Stephen K, et al, 2015 Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol 193: 1956\u20131962.","journal-title":"J Urol"},{"key":"16020115_CR36","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.eururo.2013.02.023","volume":"65","author":"N Keating","year":"2014","unstructured":"Keating N, Liu P, O\u2019Malley A, Freedland S, Smith M, 2014 Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 65: 816\u2013824.","journal-title":"Eur Urol"},{"key":"16020115_CR37","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.juro.2014.12.086","volume":"193","author":"J Morote","year":"2015","unstructured":"Morote J, Gomez-Caamano A, Alvarez-Ossorio J, et al, 2015 The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy. J Urol 193: 1963\u20131969.","journal-title":"J Urol"},{"issue":"Suppl 1","key":"16020115_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2337\/dc08-S012","volume":"31","author":"American Diabetes Association","year":"2008","unstructured":"American Diabetes Association, 2008 Standards of medical care in diabetes-2008. Diabetes Care 31: Suppl 1: 12\u201354.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"16020115_CR39","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2337\/dc09-S062","volume":"32","author":"American Diabetes Association","year":"2009","unstructured":"American Diabetes Association, 2009 Diagnosis and classification of diabetes mellitus. Diabetes Care 32: Suppl 1: 62\u201367.","journal-title":"Diabetes Care"},{"key":"16020115_CR40","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1210\/jc.2007-2595","volume":"93","author":"S Shahani","year":"2008","unstructured":"Shahani S, Braga-Basaria M, Basaria S, 2008 Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. JCEM 93: 2042\u20132049.","journal-title":"JCEM"},{"key":"16020115_CR41","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","volume":"24","author":"M Braga-Basaria","year":"2006","unstructured":"Braga-Basaria M, Dobs AS, Muller DC, et al, 2006 Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24: 3979\u20133983.","journal-title":"J Clin Oncol"},{"key":"16020115_CR42","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","volume":"370","author":"S Lewington","year":"2007","unstructured":"Prospective Study Collaboration, Lewington S, Whitlock G, Clarke R, et al, 2007 Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370: 1829\u20131839.","journal-title":"Lancet"},{"key":"16020115_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5489\/cuaj.3592","volume":"10","author":"MM Rezaei","year":"2016","unstructured":"Rezaei MM, Rezaei MM, Ghoreifi A, Kerigh BF, 2016 Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy. Can Urol Assoc J 10: 9\u201310.","journal-title":"Can Urol Assoc J"},{"key":"16020115_CR44","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.numecd.2017.02.007","volume":"27","author":"Csongr\u00e1di","year":"2017","unstructured":"Csongr\u00e1di \u00c9, K\u00e1pl\u00e1r M, Nagy B Jr, 2017 Adipokines as atherothrombotic risk factors in obese subjects: Associations with haemostatic markers and common carotid wall thickness. Nutr Metab Cardiovasc Dis 27: 571\u2013580.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"16020115_CR45","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1001\/archinte.164.13.1427","volume":"164","author":"TJ Wilt","year":"2004","unstructured":"Wilt TJ, Bloomfield HE, MacDonald R, et al, 2004 Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 164: 1427\u20131436.","journal-title":"Arch Intern Med"},{"key":"16020115_CR46","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.juro.2007.08.137","volume":"179","author":"MR Smith","year":"2008","unstructured":"Smith MR, Malkowicz SB, Chu F, et al, 2008 Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 179: 152\u2013155.","journal-title":"J Urol"},{"key":"16020115_CR47","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/andr.274","volume":"2","author":"V Zarotsky","year":"2014","unstructured":"Zarotsky V, Huang MY, Carman W, et al, 2014 Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology 2: 819\u2013834.","journal-title":"Andrology"},{"key":"16020115_CR48","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/cncr.23440","volume":"112","author":"MR Smith","year":"2008","unstructured":"Smith MR, Lee H, McGovern F, et al, 2008 Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: Differences from the classic metabolic syndrome. Cancer 112: 2188\u20132194.","journal-title":"Cancer"},{"key":"16020115_CR49","doi-asserted-by":"publisher","first-page":"820403","DOI":"10.1155\/2015\/820403","volume":"2015","author":"MK Davis","year":"2015","unstructured":"Davis MK, Rajala JL, Tyldesley S, Pickles T, Virani SA, 2015 The prevalence of cardiac risk factors in men with localized prostate cancer undergoing androgen-deprivation therapy in British Columbia, Canada. J Oncol 2015: 820403.","journal-title":"J Oncol"},{"key":"16020115_CR50","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","volume":"366","author":"KG Alberti","year":"2005","unstructured":"Alberti KG, Zimmet P, Shaw J, 2005 The metabolic syndrome: a new worldwide definition. Lancet 366: 1059\u20131062.","journal-title":"Lancet"},{"key":"16020115_CR51","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.rpor.2015.06.004","volume":"5","author":"PM Samper Ots","year":"2015","unstructured":"Samper Ots PM, Mu\u00f1oz Garc\u00eda JL, R\u00edos Kavadoy Y, et al, 2015 SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional study. Rep Pract Oncol Radiother 5: 370\u2013376.","journal-title":"Rep Pract Oncol Radiother"},{"key":"16020115_CR52","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/MED.0b013e3283398ee2","volume":"17","author":"CA Allan","year":"2010","unstructured":"Allan CA, McLachlan RI, 2010 Androgens and obesity. Curr Opin Endocrinol Diabetes Obes 17: 224\u2013232.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"16020115_CR53","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ijrobp.2013.06.934","volume":"87","author":"J Munoz Garcia","year":"2013","unstructured":"Munoz Garcia J, Samper Ots P, Rios Kavadoy Y, et al, 2013 Cross-section observational study about prevalence of metabolic syndrome and osteoporosis in prostate cancer treated with androgen-deprivation therapy and their impact on quality of life (SIMBOSPROST): Gicor Group. Intl J Rad Onc Bio Phys 87: Suppl: 356.","journal-title":"Intl J Rad Onc Bio Phys"},{"key":"16020115_CR54","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1569-9056(11)61074-9","volume":"10","author":"J Valverde","year":"2011","unstructured":"Valverde J, Planas Morin J, Salvador Lacambra C, et al, 2011 Prevalence of metabolic syndrome in prostatecancer patients under androgen-deprivation therapy: Interim results of a case-control study. Eur Urol Suppl 10: 337.","journal-title":"Eur Urol Suppl"},{"key":"16020115_CR55","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","volume":"68","author":"C Bosco","year":"2015","unstructured":"Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating N, Van Hemelrijck M, 2015 (2015a) Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol 68: 386\u2013396.","journal-title":"Eur Urol"},{"key":"16020115_CR56","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1677\/jme.0.0250085","volume":"25","author":"J Beilin","year":"2000","unstructured":"Beilin J, Ball EM, Favaloro JM, Zajac JD, 2000 Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J Mol Endocrinol 25: 85\u201396.","journal-title":"J Mol Endocrinol"},{"key":"16020115_CR57","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1530\/EJE-08-0266","volume":"159","author":"RD Stanworth","year":"2008","unstructured":"Stanworth RD, Kapoor D, Channer KS, Jones TH, 2008 Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. Eur J Endocrinol 159: 739\u2013746.","journal-title":"Eur J Endocrinol"},{"key":"16020115_CR58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00125-002-0980-9","volume":"46","author":"M Zitzmann","year":"2003","unstructured":"Zitzmann M, Gromoll J, von Eckardstein A, Nieschlag E, 2003 The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men. Diabetologia 46: 31\u201339.","journal-title":"Diabetologia"},{"key":"16020115_CR59","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1530\/EJE-10-1022","volume":"164","author":"M M\u00f6hlig","year":"2011","unstructured":"M\u00f6hlig M, Arafat AM, Osterhoff MA, et al, 2011 Androgen receptor CAG repeat length polymorphism modifies the impact of testosterone on insulin sensitivity in men. Eur J Endocrinol 164: 1013\u20131018.","journal-title":"Eur J Endocrinol"},{"key":"16020115_CR60","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1365-2796.2004.01426.x","volume":"257","author":"ME Trujillo","year":"2005","unstructured":"Trujillo ME, Scherer PE, 2005 Adiponectin journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 257: 167\u2013175.","journal-title":"J Intern Med"},{"key":"16020115_CR61","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2010.03942.x","volume":"3","author":"EJ Hamilton","year":"2011","unstructured":"Hamilton EJ, Gianatti E, Strauss BJ, et al, 2011 Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol 3: 377\u2013383.","journal-title":"Clin Endocrinol"},{"key":"16020115_CR62","doi-asserted-by":"publisher","first-page":"e3873","DOI":"10.1097\/MD.0000000000003873","volume":"95","author":"LM Scailteux","year":"2016","unstructured":"Scailteux LM, Naudet F, Alimi Q, 2016 Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: A systematic review with direct and network meta-analyses of randomized controlled trials and observational studies. Medicine (Baltimore) 95: e3873.","journal-title":"Medicine (Baltimore)"},{"key":"16020115_CR63","doi-asserted-by":"publisher","first-page":"3A","DOI":"10.1016\/j.amjcard.2005.11.010","volume":"97","author":"SM Haffner","year":"2006","unstructured":"Haffner SM, 2006 The metabolic syndrome: Inflammation, diabetes mellitus and cardiovascular disease. Am J Cardiol 97: 3A\u201311A.","journal-title":"Am J Cardiol"},{"key":"16020115_CR64","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","volume":"167","author":"L Berruti","year":"2002","unstructured":"Berruti L, Dogliotti C, Terrone, et al, 2002 Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167: 2361\u20132367.","journal-title":"J Urol"},{"key":"16020115_CR65","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.eururo.2012.04.035","volume":"64","author":"NL Keating","year":"2013","unstructured":"Keating NL, O\u2019Malley AJ, Freedland SJ, Smith MR, 2013 Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol 64: 159\u2013166.","journal-title":"Eur Urol"},{"key":"16020115_CR66","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/1756287215617872","volume":"8","author":"P Zareba","year":"2016","unstructured":"Zareba P, Duivenvoorden W, Leong DP, Pinthus JH, 2016 Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther Adv Urol 8: 118\u2013129.","journal-title":"Ther Adv Urol"},{"key":"16020115_CR67","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1093\/jnci\/djm168","volume":"99","author":"HK Tsai","year":"2007","unstructured":"Tsai HK, D\u2019Amico AV, Sadetsky N, et al, 2007 Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99: 1516\u20131524.","journal-title":"J Natl Cancer Inst"},{"key":"16020115_CR68","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1200\/JCO.2007.12.3752","volume":"27","author":"JA Efstathiou","year":"2009","unstructured":"Efstathiou JA, Bae K, Shipley WU, et al, 2009 Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 27: 92\u201399.","journal-title":"J Clin Oncol"},{"key":"16020115_CR69","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1200\/JCO.2007.13.9881","volume":"26","author":"M Roach III","year":"2008","unstructured":"Roach III M, Bae K, Speight J, et al, 2008 Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 86-10. J Clin Oncol 26: 585\u2013591.","journal-title":"J Clin Oncol"},{"key":"16020115_CR70","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.eururo.2008.01.021","volume":"54","author":"JA Efstathiou","year":"2008","unstructured":"Efstathiou JA, Bae K, Shipley WU, et al, 2008 Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 54: 816\u2013824.","journal-title":"Eur Urol"},{"key":"16020115_CR71","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1001\/jama.2011.1745","volume":"306","author":"PL Nguyen","year":"2011","unstructured":"Nguyen PL, Je Y, Schutz FA, et al, 2011 Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306: 2359\u20132366.","journal-title":"JAMA"},{"key":"16020115_CR72","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","volume":"360","author":"M Bolla","year":"2009","unstructured":"Bolla M, de Reijke TM, Van Tienhoven G, et al, 2009 Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360: 2516\u20132527.","journal-title":"N Engl J Med"},{"key":"16020115_CR73","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","volume":"291","author":"JF Piccirillo","year":"2004","unstructured":"Piccirillo JF, Tierney RM, Costas I, et al, 2004 Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291: 2441\u20132447.","journal-title":"JAMA"},{"key":"16020115_CR74","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.juro.2011.07.035","volume":"186","author":"MR Smith","year":"2011","unstructured":"Smith MR, Klotz L, van der Meulen E, et al, 2011 Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol 186: 1835\u20131842.","journal-title":"J Urol"},{"key":"16020115_CR75","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","volume":"65","author":"PC Albertsen","year":"2014","unstructured":"Albertsen PC, Klotz L, Tombal B, et al, 2014 Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 65: 565\u2013573.","journal-title":"Eur Urol"},{"key":"16020115_CR76","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1001\/jama.282.21.2012","volume":"282","author":"J Stamler","year":"1999","unstructured":"Stamler J, Stamler R, Neaton JD, et al, 1999 Low risk-factor profile and long-term cardiovascular and non-cardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 282: 2012\u20132018.","journal-title":"JAMA"},{"key":"16020115_CR77","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3810\/pgm.2014.11.2831","volume":"126","author":"TH Lim","year":"2014","unstructured":"Lim TH, Orija IB, Pearlman BL, 2014 American College of Cardiology; American College of Cardiology. The new cholesterol treatment guidelines from the American College of Cardiology\/American Heart Association, 2013: what clinicians need to know. Postgrad Med 126: 35\u201344.","journal-title":"Postgrad Med"},{"key":"16020115_CR78","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3389\/fonc.2016.00200","volume":"6","author":"BA Wall","year":"2016","unstructured":"Wall BA, 2016 Androgen deprivation therapy and cardiovascular disease risk \u2014 The role of exercise in prostate cancer treatment. Frontiers in Oncology 6: 200.","journal-title":"Frontiers in Oncology"},{"key":"16020115_CR79","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1200\/JCO.2009.23.2488","volume":"28","author":"DA Galv\u00e3o","year":"2010","unstructured":"Galv\u00e3o DA, Taaffe DR, Spry N, 2010 Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 28: 340\u2013347.","journal-title":"J Clin Oncol"},{"key":"16020115_CR80","doi-asserted-by":"crossref","unstructured":"Taaffe DR, Newton RU, Spry N, 2017 Effects of different exercise modalities on fatigue in prostate cancer patients undergoing androgen deprivation therapy: A year-long randomised controlled trial. Eur Urol [Epub ahead of Print].","DOI":"10.1016\/j.eururo.2017.02.019"},{"key":"16020115_CR81","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1007\/s11764-016-0543-6","volume":"10","author":"CJ Gaskin","year":"2016","unstructured":"Gaskin CJ, Fraser SF, Owen PJ, Craike M, Orellana L, Livingston PM, 2016 Fitness outcomes from a randomised controlled trial of exercise training for men with prostate cancer: the ENGAGE study. J Cancer Surviv 10: 972\u2013980.","journal-title":"J Cancer Surviv"},{"key":"16020115_CR82","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1530\/ERC-15-0456","volume":"23","author":"L Teleni","year":"2016","unstructured":"Teleni L, Chan RJ, Chan A, 2016 Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials. Endocr Relat Cancer 23: 101\u2013112.","journal-title":"Endocr Relat Cancer"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.14310\/horm.2002.1727.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.14310\/horm.2002.1727\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.14310\/horm.2002.1727.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T15:40:03Z","timestamp":1739115603000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.14310\/horm.2002.1727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["16020115"],"URL":"https:\/\/doi.org\/10.14310\/horm.2002.1727","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"30 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}